ADVERTISEMENT

CCL Products Q3 Results Review - Inline Quarter; Better Growth Visibility Drives New Capex: Systematix

Increasing scale of business, sustained client acquisition, product development initiatives are helping drive strong share gains.

<div class="paragraphs"><p>Coffee beans are roasted inside a  coffee roaster. (Photo: Gregory-Hayes/ Unsplash)</p></div>
Coffee beans are roasted inside a coffee roaster. (Photo: Gregory-Hayes/ Unsplash)

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. 

Systamatix Research Report

CCL Products India Ltd.’s Q3 FY23 result was broadly inline with our expectations, with 27%/9%/25% YoY growth in revenue/Ebitda/profit after tax, respectively.

Volume growth fell to low single digit, given a 20-day maintenance shutdown in India plant, and some disruptions in Vietnam related to new capacity commissioning.

However, management maintained its FY23 volume growth guidance of 20-25%, with incremental volumes from Vietnam expected Q4 onwards. High coffee inflation resulted in ~20% increase in realisations, which optically drove Ebitda margin 310 basis points lower to 18.8%.

Increasing scale of business, sustained client acquisition and product development initiatives are helping drive strong share gains for the company across U.S., Europe, India and South-East Asia, as reflected from CCL Products’ strong order bookings for FY24.

Restructuring in the domestic business led to growth momentum slowing to 25% from 35% plus, with FY23 revenue targeted at Rs 2.5 billion. While the new India plant is on track to get commissioned in Q1 FY25, the company has announced another new 6,000 million tonne freeze-dried coffee plant in Vietnam at an outlay of $50 million, slated to come up by Q3 FY25.

Click on the attachment to read the full report:

Systematix CCL Products - Q3FY23 Results Review.pdf

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.